Roche: positive results in haemophilia phase III studies.
(CercleFinance.com) - Roche's drug emicizumab has showed positive results in phase III studies in haemophilia A with inhibitors, the Swiss drugmaker said on Monday.
The investigational monoclonal antibody showed a statistically significant and clinically meaningful reduction in bleed rate of 87%, with emicizumab prophylaxis compared with on-demand treatment with bypassing agents, the company said.
Likewise, after a median observation time of 31 weeks, 62.9% of patients receiving emicizumab experienced zero treated bleeds compared to 5.6% of those receiving on-demand bypassing agents.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The investigational monoclonal antibody showed a statistically significant and clinically meaningful reduction in bleed rate of 87%, with emicizumab prophylaxis compared with on-demand treatment with bypassing agents, the company said.
Likewise, after a median observation time of 31 weeks, 62.9% of patients receiving emicizumab experienced zero treated bleeds compared to 5.6% of those receiving on-demand bypassing agents.
Copyright (c) 2017 CercleFinance.com. All rights reserved.